A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...

Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a ...

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday ...

British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the ...

Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...

The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...

Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...

AstraZeneca announced on Monday that it has secured approval from the US Food and Drug Administration, alongside Daiichi ...

The U.S. Food and Drug Administration approved AstraZeneca (AZN, AZN.L) and Daiichi Sankyo's (DSKYF.PK) Datroway (datopotamab ...

The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...